| abstract |
The invention relates to an agent for influencing angiogenesis, i.e. the new formation of blood vessels. The application areas for this agent are the medical field and the pharmaceutical industry. The aim of the invention is to discover new agents for influencing angiogenesis and to provide corresponding substances that can be used in the medical field to produce said agents. The inventive agent is characterised in that it influences angiogenesis, i.e. promotes or inhibits the latter. The promotion of angiogenesis is achieved, for example, by increasing the synthesis of the B1 receptor (transcription-mediated amplification, e.g. by cytokines), or by increasing its activity (agonistic substances). The inhibition of angiogenesis is achieved, for example, by antagonists of the kinin B1 receptor, such as des-Arg<9>-Leu<8>-bradykinin (DALBK) or non-peptide substances and by inhibiting the synthesis of the protein, e.g. using glucucorticoids. |